PI4KIII? is a therapeutic target in chromosome 1q-amplified lung adenocarcinoma.

ABSTRACT: Heightened secretion of protumorigenic effector proteins is a feature of malignant cells. Yet, the molecular underpinnings and therapeutic implications of this feature remain unclear. Here, we identify a chromosome 1q region that is frequently amplified in diverse cancer types and encodes multiple regulators of secretory vesicle biogenesis and trafficking, including the Golgi-dedicated enzyme phosphatidylinositol (PI)-4-kinase III? (PI4KIII?). Molecular, biochemical, and cell biological studies show that PI4KIII?-derived PI-4-phosphate (PI4P) synthesis enhances secretion and accelerates lung adenocarcinoma progression by activating Golgi phosphoprotein 3 (GOLPH3)-dependent vesicular release from the Golgi. PI4KIII?-dependent secreted factors maintain 1q-amplified cancer cell survival and influence prometastatic processes in the tumor microenvironment. Disruption of this functional circuitry in 1q-amplified cancer cells with selective PI4KIII? antagonists induces apoptosis and suppresses tumor growth and metastasis. These results support a model in which chromosome 1q amplifications create a dependency on PI4KIII?-dependent secretion for cancer cell survival and tumor progression.

SUBMITTER: Tan X 

PROVIDER: S-EPMC7702266 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature